Healthcare stocks have been buffeted by uncertainty on many fronts, including the outlook for US drug pricing, broader macro concerns such as taxation policy, and a strengthening US Dollar.
This drove underperformance of healthcare vs the wider markets in H2 2016. Strong dispersion in sub-sector multiples ensued, with rotation out of “riskier” pharma/biotech into perceived safer havens such as lab tools and services players.
To get access to the full Healthcare & Life Sciences Sector Note - please click here
